EFTA01955010.pdf

To: EFTA_R1_00424760 EFTA01955010 From: Steven Victor MD Sent: Thur 10/10/2013 8:32:55 PM Subject: MD GLOBAL PARTNERS ADVISORS IntelliCell Biosciences Engages MD Global Partners, LLC as Advisor to the Company Press Release: Intl:hit:ell Wasciences, Inc — t hour 35 Jimmies ivd,i) Email Print RELATED QUOTES Symbol Price Change SVFC 0.0106 -0.0018 NEW YORK, NY--(Marketwired - Oct to, 2013) - IntelliCell Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular fraction cells (SVFCs) derived from the blood vessels in lipoaspirate, announced today that it has engaged MD Global Partners, LLC to advise on the company's restructuring, corporate positioning, and strategic opportunities. The influx of capital structure will allow, the Company to expand its FDA cGTP cellular laboratories into Hospitals and Ambulatory Surgical Centers. This will also enable IntelliCell to initiate a FDA IND clinical study, vital for the development of the company. Dr. Steven Victor said, "I am privileged that Mr. Owen May, Managing Director of MD Global Partners, is going to lead in the Company's restructuring and strategic positioning. With his years of experience and expertise, Mr. May will be instrumental in assisting us to achieve our strategic milestones. Mr. EFTA_R1_00424761 EFTA01955011  May, a graduate of Duke University's Fuqua School of Business, is a seasoned professional with decades of experience in helping assisting emerging growth companies, similar to IntelliCell achieve their goals." Dr. Steven Victor, Chairman and CEO of IntelliCell Biosciences, commented, "IntelliCell believes that we possess a paradigm shifting discovery that will change the manner in which patients are treated," Dr. Victor continued. "We are confident that our relationships with the FDA and other governing bodies will allow us to rapidly expand the number of patients that physicians at ReGen Medical, PC can treat using IntelliCell's SFV cellular therapy." About MI) Global Partners M D Global Partners, LLC ("MDG") is an independent full service investment bank focused on small to middle market public and private companies. The Firm brings an integrated strategic, operating and financial approach in assisting small companies realize the benefits of conventional investment banking services throughout the life cycle. Its senior team has extensive transaction execution experience and strong relationships with a variety of investors including family offices and individual/institutional investors, both domestic and global. MDG's wide spectrum of service offerings combined with its global, diverse investor network, uniquely positions itself to provide advice and find optimal investor groups to its clients. About IntelliCell Biosciences IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. One of the revenue streams IntelliCell is pursuing is placing its labs into Hospitals and Ambulatory Surgical Centers. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities. Forward-Looking Statements Certain statements set forth in this press release constitute "forward-looking statements." Forward- looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission. Contact: EFTA_R1_00424762 EFTA01955012  Contact Investors: Chris Camarra Alliance Advisors, LLC Email Contact Steven Victor MD IntelliCell BioSciences Chairman/CEO 460 Park Avenue 17th Floor 1000 Y Y 10022 www nte e ciences.com EFTA_R1_00424763 EFTA01955013